Mandana Khalili, MD

Professor of Medicine, UCSF; Chief of Clinical Hepatology and Director of Clinical and Translational Research in Hepatology, Zuckerberg San Francisco General Hospital (ZSFG)

Cancer Center Program Membership

Cancer Control

Research Summary

Mandana Khalili is a Professor of Medicine in the Department of Medicine and Chief of Clinical Hepatology at Zuckerberg San Francisco General Hospital (ZSFG). She also serves as the Director of Clinical and Translational Research in Hepatology at ZSFG. Her research focuses on assessing and addressing health disparities related to viral hepatitis, nonalcoholic fatty liver disease, alcohol-associated liver disease, cirrhosis, and hepatocellular carcinoma including natural history, pathogenesis, metabolic complications, healthcare access and novel treatments. She has a longstanding track record of extramural funding in these areas and has served as PI or co-PI of several NIH-sponsored national and international networks. She currently serves as a PI for the NIDDK-sponsored Liver Cirrhosis Network and also Hepatitis B Research Network assessing the natural history and optimal management of patients with hepatitis B and cirrhosis. Her group previously evaluated mechanisms of insulin resistance and secretion in Latinos with and without hepatitis C infection and is now examining how alcohol affects insulin action and adipose tissue insulin resistance among this at high-risk populations. In collaboration with two VA hospitals, she is evaluating the impact of COVID pandemic and transitions in care delivery on telemedicine satisfaction, quality of life, cirrhosis management, liver cancer screening and substance use among vulnerable populations in order to implement measures and policies to provide equitable liver care. Her group is also evaluating alcohol treatment in patients with liver disease using a novel stepped care motivational interviewing and addiction medicine treatment in the hepatology setting. Additional studies include examining patient and provider knowledge, attitudes and barriers to viral hepatitis and fatty liver disease management and implementing novel patient-centered as well as provider interventions such as education through mobile app to enhance patient care and address barriers to care. Her group’s recent efforts in developing an integrated model of shelter-based hepatitis C screening and treatment within large homeless shelters in San Francisco and Minnesota has been successful in scaling up hepatitis C management in persons who inject drugs and homeless residents. She is a member of the Liver Cancer San Francisco Cancer Initiative (SF-CAN), which in partnership with the City and County of San Francisco and other health and community partners, is using interventional strategies to reduce cancer in the city. Dr. Khalili is passionate about mentoring trainees and junior faculty and she has mentored numerous trainee and faculty at all career stages. She is a recipient of a NIH-sponsored K24 award in mentoring junior investigators in liver disease and the co-Director (co-PI) of the T32 Training in Hepatology. She has campus wide leadership roles in mentoring as the Director of UCSF Mentor Training Program. She also currently serves as the Director of Investigator Development Unit of the Research Coordinating Center to Reduce Disparities in Multiple Chronic Diseases sponsored by NIMHD. Her diverse research program including translational research, natural history and epidemiology, community/participatory research, health services/disparity, and clinical trials provides the infrastructure for supporting junior investigators and in transitioning them to independence.

Research Funding

  • August 15, 2023 - May 31, 2028 - Dissecting the Acid Ceramidase Pathway in Hepatic Fibrogenesis , Co-Investigator . Sponsor: NIH/NIDDK, Sponsor Award ID: R01DK134723-01A1
  • December 22, 2021 - December 31, 2026 - Racial and Ethnic Disparities in Hepatocellular Carcinoma Surveillance Among Patients with Cirrhosis Across Five Safety Net Organizations , UCSF Site Principal Investigator/Co-Investigator . Sponsor: NIH/NIMHD, Sponsor Award ID: R01MD017063
  • September 6, 2021 - August 31, 2026 - Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies , Principal Investigator . Sponsor: NIH, Sponsor Award ID: U01DK130168
  • September 1, 2021 - August 31, 2026 - Research Coordinating Center to Reduce Disparities in Multiple Chronic Diseases (RCC RD-MCD) , Director Investigator Skill Development Unit and Co-Investigator . Sponsor: NIH/NIMHD, Sponsor Award ID: U24MD017250


2022 - Diversity, Equity, and Inclusion Champion Training, University of California San Francisco
Mentor Development Program Certificate, 2007 - Research Mentoring, UCSF
M.A.S, 2005 - Masters in Advanced Studies in Clinical and Epidemiologic Research, UCSF
Transplant Hepatology, 1999 - Transplant Hepatology and Post-Doctoral Research, UCSF
Hepatology, 1998 - Hepatology, Ochsner Clinic
Gastroenterology, 1997 - Gastroenterology, McGill University
M.D., 1992 - Medicine, University of Ottawa

Honors & Awards

  • Harold L. Luft Award, Health Disparity Mentoring Award Nomination, UCSF, 2023
  • ZSFG Department of Medicine Mentoring Award, UCSF, 2023
  • Zuckerberg San Francisco DOM Physician COVID-19 Clinical Service Recognition Award, UCSF, 2022
  • Affiliate Faculty, UCSF Philip R. Lee Institute for Health Policy Studies, 2022
  • Visiting Professor, Department of Scientific Research, Peking Union Medical College, Beijing, China, 2019
  • Certificate of Appreciation-Mentor Training Program, Peking Union Medical College, Beijing, China, 2018
  • Harold L. Luft Award, Health Disparity Mentoring Award Nomination, UCSF, 2017
  • ZSFG Distinction in Medical Education Award Nomination, UCSF, 2016
  • Academic Senate Distinction in Mentoring Award Nomination, UCSF, 2015
  • Mid-Career Investigator Award in Patient Oriented Research, NIH, 2014
  • Academic Senate Distinction in Mentoring Award Nomination, UCSF, 2013
  • UCSF University Community Partnerships Council Service Learning Award, UCSF, 2009
  • Longitudinal Clinical Experience Appreciation Certificate, UCSF, 2008
  • Recognizing Discovery and Innovation in 2001: Milestones in Hepatitis C, Hepatitis Innovation Award, Schering Oncology, 2001
  • American Digestive Health Foundation, Martin Brotman Training and Transition Award, Gastroenterology Research Group, 2000
  • Natural Sciences and Engineering Research Council Award, Canada, 1988
  • J.W. McConnell Entrance Award, McGill University, 1986

Selected Publications

  1. Kim RG, Patel S, Satre DD, Shumway M, Chen JY, Magee C, Wong RJ, Monto A, Cheung R, Khalili M. Telehepatology Satisfaction Is Associated with Ethnicity: The Real-World Experience of a Vulnerable Population with Fatty Liver Disease. Dig Dis Sci. 2024 Jan 13.  View on PubMed
  2. Choi HH, Kim S, Shum DJ, Huang CY, Shui A, Fox RK, Khalili M. Assessing Adherence to US LI-RADS Follow-up Recommendations in Vulnerable Patients Undergoing Hepatocellular Carcinoma Surveillance. Radiol Imaging Cancer. 2024 Jan; 6(1):e230118.  View on PubMed
  3. Wong RJ, Yang Z, Ostacher M, Zhang W, Satre D, Monto A, Khalili M, Singal AK, Cheung R. Alcohol Use Patterns During and After the COVID-19 Pandemic Among Veterans in the United States. Am J Med. 2023 Dec 03.  View on PubMed
  4. Shyam Patel, Rebecca G. Kim, Amy M. Shui, Catherine Magee, Maggie Lu, Jennifer Chen, Michele Tana, Chiung-Yu Huang, Mandana Khalili. Fatty Liver Education Promotes Physical Activity in Vulnerable Groups, Including Those with Unhealthy Alcohol Use. Gastro Hep Advances. 2023.  View on PubMed
  5. Evon DM, Lin HS, Khalili M, Wahed AS, Yim C, Fontana RJ, Hoofnagle JH, Hepatitis B Research Network (HBRN). Symptoms of Liver Disease During Tenofovir Therapy With or Without Peginterferon: Results from the Hepatitis B Research Network Immune Active Trial. Dig Dis Sci. 2023 12; 68(12):4499-4510.  View on PubMed
  6. Klepper A, Kung A, Vazquez SE, Mitchell A, Mann S, Zorn K, Avila-Vargas I, Kari S, Tekeste M, Castro J, Lee B, Duarte M, Khalili M, Yang M, Wolters P, Price J, Perito E, Feng S, Maher JJ, Lai J, Weiler-Normann C, Lohse AW, DeRisi J, Tana M. Novel autoantibody targets identified in patients with autoimmune hepatitis (AIH) by PhIP-Seq reveals pathogenic insights. medRxiv. 2023 Jun 27.  View on PubMed
  7. Medina SP, Kim RG, Magee C, Stapper N, Khalili M. Cross-sectional study on stigma and motivation to adhere to lifestyle modification among vulnerable populations with fatty liver disease. Obes Sci Pract. 2023 Dec; 9(6):581-589.  View on PubMed
  8. Lisker-Melman M, King WC, Ghany MG, Chung RT, Hinerman AS, Cloherty GA, Khalili M, Jain MK, Sulkowski M, Sterling RK. Human immunodeficiency virus coinfection differentially impacts hepatitis B virus viral markers based on hepatitis Be antigen status in patients with suppressed viremia. J Viral Hepat. 2023 08; 30(8):700-709.  View on PubMed
  9. Ghany MG, King WC, Hinerman AS, Lok AS, Lisker-Melman M, Chung RT, Terrault N, Janssen HLA, Khalili M, Lee WM, Lau DTY, Cloherty GA, Sterling RK. Use of HBV RNA and to predict change in serological status and disease activity in CHB. Hepatology. 2023 11 01; 78(5):1542-1557.  View on PubMed
  10. Kleiner DE, Lisker-Melman M, Wahed AS, Bhan AK, Nalesnik MA, Choi EK, Leonard KK, Ghany MG, Chung RT, Di Bisceglie AM, Hepatitis B Research Network. Immunostaining for hepatitis B viral antigens in liver: Association with clinical, biochemical, and virologic features of disease. J Gastroenterol Hepatol. 2023 Jun; 38(6):989-998.  View on PubMed
  11. Khalili M, Leonard KR, Ghany MG, Hassan M, Roberts LR, Sterling RK, Belle SH, Lok AS, Hepatitis B Research Network. Racial Disparities in Treatment Initiation and Outcomes of Chronic Hepatitis B Virus Infection in North America. JAMA Netw Open. 2023 04 03; 6(4):e237018.  View on PubMed
  12. Feld JJ, Wahed AS, Fried M, Ghany MG, Di Bisceglie AM, Perrillo RP, Khalili M, Yang X, Belle SH, Janssen HLA, Terrault N, Lok AS, Hepatitis B Research Network (HBRN). Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment Trial. Am J Gastroenterol. 2023 07 01; 118(7):1226-1236.  View on PubMed
  13. Khalili M, Kim NJ, Tsoh JY, Walsh JME, Elizabeth Goldman L, Park H, Lau I, Wong C, Gildengorin G, Nguyen TT. Efficacy of a Primary Care-Based Mobile Application to Increase Hepatitis C Screening Among Asian Americans: A Secondary Analysis of a Randomized Clinical Trial. Open Forum Infect Dis. 2023 Jan; 10(1):ofad002.  View on PubMed
  14. Terrault NA, Lok AS, Wahed AS, Ghany MG, Perrillo RP, Fried MW, Wong DK, Khalili M, Lau DTY, Sterling RK, Di Bisceglie AM, Lisker-Melman M, Cooper SL, Chung RT, Patel K, Roberts LR, Belle SH, Janssen HLA, Hepatitis B Research Network. Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B. Am J Gastroenterol. 2023 07 01; 118(7):1214-1225.  View on PubMed
  15. Cheng YW, McLean R, Sewell JL, Huang CY, Khalili M. Inflammatory bowel disease type influences development of elevated liver enzymes. JGH Open. 2022 Dec; 6(12):846-853.  View on PubMed
  16. Kim RG, Deng J, Reaso JN, Grenert JP, Khalili M. Noninvasive Fibrosis Screening in Fatty Liver Disease Among Vulnerable Populations: Impact of Diabetes and Obesity on FIB-4 Score Accuracy. Diabetes Care. 2022 10 01; 45(10):2449-2451.  View on PubMed
  17. Kim RG, Khalili M. Undiagnosed abnormal alanine transaminase levels in vulnerable populations: Impact of sex, race/ethnicity, and body mass. Obes Sci Pract. 2023 Apr; 9(2):190-199.  View on PubMed
  18. Kim RG, Chu JN, Vittinghoff E, Deng J, Reaso JN, Grenert JP, Khalili M. Racial/ethnic differences in fibrosis prevalence and progression in biopsy-proven steatosis: A focus on the Asian American population. Hepatol Commun. 2022 Nov; 6(11):3024-3035.  View on PubMed
  19. Lisker-Melman M, Wahed AS, Ghany MG, Chung RT, King WC, Kleiner DE, Bhan AK, Khalili M, Jain MK, Sulkowski M, Wong DK, Cloherty G, Sterling RK. HBV transcription and translation persist despite viral suppression in HBV-HIV co-infected patients on antiretroviral therapy. Hepatology. 2023 02 01; 77(2):594-605.  View on PubMed
  20. Feld JJ, King WC, Ghany MG, Chang KM, Terrault N, Perrillo RP, Khalili M, Hinerman AS, Janssen H, Lok AS, Hepatitis B Research Network (HBRN). Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2023 06; 21(6):1503-1512.e4.  View on PubMed

Go to UCSF Profiles, powered by CTSI